Results 121 to 130 of about 5,445 (182)

Validation of Combining Total Kidney Volume and Kidney Failure Risk Equation in Autosomal Dominant Polycystic Kidney Disease. [PDF]

Kidney Int Rep
Bevilacqua M, Guan M, Romann A, Er L, Shao T, Farah M, Elliott MD.   +6 more
europepmc   +1 more source

Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Real-World Insights from a Propensity Score Weighted Retrospective Cohort Study.

Am J Nephrol
Marshall WR, Chinnadurai R, Rengarajan S, De Bhailís Á, Gorton J, Kalra PA, Wood G.   +6 more
europepmc   +1 more source

SAR-Guided Scaffold Innovation of Selective V₂R Antagonists: Therapeutic Frontiers in ADPKD. [PDF]

ACS Med Chem Lett
Shi H, Li Y, Liang SH.
europepmc   +1 more source

Long-Term Tolvaptan Administration in Chinese Patients with Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study in Real Clinical Practice.

Kidney Blood Press Res
Li M, Sun M, Cui S, Liu X, Guo M, Xiao Y, Huang Y, Zhou S, Wang H, Chen X, Li Q.   +10 more
europepmc   +1 more source

Clinical trial on the pharmacokinetics, pharmacodynamics and safety of tolvaptan in healthy Chinese males: an open-label, single and multiple dosage, parallel group study. [PDF]

Front Pharmacol
Liu H, Liu T, Liu M, Zheng X, Zhong W, Zhao Q, Jiang J, Hu P, Li Y.   +8 more
europepmc   +1 more source

Sodium-Glucose Cotransporter-2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes. [PDF]

Kidney Int Rep
Catania M, Rivera RF, Kola K, De Rosa LI, Paolisi M, Bianca P, Vezzoli G, Sciarrone Alibrandi MT.   +7 more
europepmc   +1 more source

Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials. [PDF]

Eur Heart J Cardiovasc Pharmacother
Cannatà A, Anastasia G, De Marzo V, Caspi O, Bromage D, Porto I, Savarese G, McDonagh T, Cox ZL, Ameri P.   +9 more
europepmc   +1 more source

Structural insights into antagonist recognition by the vasopressin V2 receptor. [PDF]

Nat Commun
Zhang T, Liu H, You C, Zhang Y, Xu Y, Pan B, Wu C, Jin S, Yin YL, Wu K, Chen Y, Sun H, Si Y, Tan Y, Yin W, Xu HE, Guo D, Jiang Y.   +17 more
europepmc   +1 more source

Refining Tolvaptan Dosing in Autosomal Dominant Polycystic Kidney Disease. [PDF]

Kidney360
Dahl NK, Torres VE.
europepmc   +1 more source

Renal Tubule-Specific Deletion of Nephrocystin 3 <i>(Nphp3)</i> Causes Infantile Nephronophthisis-like Phenotypes in Mice. [PDF]

Int J Mol Sci
Du X, Wang C, Fang Y, Wang G, Zhai Y, Shen Q, Tang X, Xu H.   +7 more
europepmc   +1 more source